AUS
NZ
UK
CA
USA
IND
Zentek Ltd. (TSXV: ZEN | NASDAQ: ZTEK), an intellectual property and advanced materials firm based in Guelph, Ontario, has announced its agreement with Atrium Research Corporation to provide company-sponsored research coverage starting July 15, 2026. Under this contract, Atrium will deliver research reports on Zentek and conduct two recorded management interviews during an initial 18-month period, compensated at $13,200 per quarter. This initiative coincides with Zentek's advancement of its Albany Graphite Project toward a Preliminary Economic Assessment (PEA) slated for completion this summer, alongside ongoing commercial revenue generation from its ZenGUARD™ air filtration technology. Investors may interpret this move as Zentek’s effort to enhance visibility among institutional and retail investors amid significant operational developments.
Key Highlights
- Zentek Ltd. (TSXV: ZEN | NASDAQ: ZTEK) is a Canadian advanced materials and graphene-enabled technology company headquartered in Guelph, Ontario.
- The company has engaged Atrium Research Corporation for sponsored research coverage, which includes published reports and two recorded management interviews.
- Atrium will receive $13,200 quarterly in cash for an initial term of 18 months starting July 15, 2026, with automatic quarterly renewals unless terminated; the agreement requires TSXV approval.
- Investors are closely monitoring progress on the Albany Graphite PEA, targeted for summer 2026 completion, and commercial revenue from the ZenGUARD™ platform.
Zentek Retains Atrium Research for Institutional-Grade Sponsored Equity Coverage
On July 15, 2026, Zentek Ltd. officially announced its engagement of Atrium Research Corporation to initiate and sustain sponsored research coverage. Distributed via Newsfile, the statement describes Atrium as a provider of institutional-quality, company-sponsored research on North American public equities. Atrium will produce detailed research reports based on publicly available data, industry insights, and discussions with Zentek’s management.
Beyond written reports, the agreement includes two recorded interviews with Zentek’s management team to discuss the company’s strategic direction and operations, making this information accessible to a broad investor base. The announcement clarifies that Atrium and Zentek maintain an arm’s-length relationship, with neither Atrium nor its insiders holding any shares or options in Zentek’s outstanding capital, ensuring transparency regarding potential conflicts of interest.
Contract Details: $13,200 Quarterly Fee for 18-Month Initial Term
The disclosed financial terms specify that Atrium will be compensated $13,200 per quarter for its research services. The initial contract term spans 18 months beginning July 15, 2026. After this period, the agreement will automatically renew on a quarterly basis at the same rate unless either party opts to terminate or renegotiate.
This engagement is contingent upon approval by the TSX Venture Exchange, consistent with regulatory requirements for TSXV-listed companies. Zentek’s dual listing on the TSXV (symbol ZEN) and NASDAQ (symbol ZTEK) positions it across Canadian and U.S. equity markets.
CEO’s Perspective: Research Coverage Supports Albany Graphite and ZenGUARD™ Milestones
Zentek CEO Mohammed (Moe) Jiwan linked the decision to secure sponsored research coverage with the company’s operational milestones. Jiwan highlighted that the coverage will offer investors comprehensive insights into the Albany Graphite Project, advancing toward a Preliminary Economic Assessment expected this summer, and the ZenGUARD™ platform, which is currently generating commercial revenue. He also noted successful bench-scale purification of Albany graphite to 5N purity, meeting nuclear-grade and defense market standards.
Jiwan emphasized that access to in-depth research will assist investors in evaluating the company as the PEA concludes and other initiatives progress. All quoted remarks are sourced directly from Zentek’s announcement and represent management’s characterization of the company’s activities and prospects.
Albany Graphite Project: Critical Minerals Asset Targeting Nuclear and Defense Sectors
A core element of Zentek’s investor narrative is the Albany Graphite Project, an igneous-hosted graphite deposit in Northern Ontario owned via the wholly owned subsidiary Albany Graphite Corp. Independent bench-scale testing, conducted with American Energy Technologies Company and previously disclosed on September 22, 2025, confirmed ultra-high purity of 99.9992% and boron concentration of 2.60 ppm, meeting benchmarks for nuclear-grade applications.
The project aims to become a North American domestic source of critical-grade graphite for nuclear, battery, and defense supply chains. Both the Canadian government and U.S. Department of Energy classify graphite as a critical mineral, increasing investor interest in North American graphite developers. The Albany Graphite PEA is targeted for completion in summer 2026, though no exact date has been specified.
ZenGUARD™ Air Filtration Platform Driving Commercial Revenue
In addition to its critical minerals focus, Zentek’s ZenGUARD™ air filtration technology platform is an active revenue-generating business segment. Management confirmed that ZenGUARD™ is already producing commercial revenue, differentiating it from the Albany Graphite Project, which remains in development. Specific revenue figures, contract counts, or product deployment volumes were not disclosed.
ZenGUARD™ is part of Zentek’s portfolio of graphene-enabled advanced material technologies targeting clean air applications. The company’s three primary platforms include Albany Graphite, ZenGUARD™, and Triera, with no further operational details on Triera provided in this announcement. Investors seeking additional financial or operational data should consult Zentek’s regulatory filings and prior corporate updates.
About Atrium Research: Approach, Founders, and Market Role
Atrium Research Corporation is described as a provider of institutional-quality, company-sponsored research on North American public equities. Its investment philosophy adopts a three- to five-year horizon, focusing on equities perceived as undercovered by the market. Atrium emphasizes analyzing key company performance metrics, management quality, and conducting thorough valuation assessments.
The firm is wholly owned and operated by co-founders Ben Pirie and Nicholas Cortellucci. No additional biographical details were provided. As a company-sponsored research provider, Atrium’s coverage of Zentek is produced under a commercial agreement, and investors should consider this context when reviewing any research reports, consistent with regulatory disclosure standards.
Arm’s-Length Status and No Equity Holdings Ensure Research Independence
Zentek’s announcement explicitly confirms the arm’s-length relationship between the company and Atrium. Neither Atrium nor its insiders hold shares or options in Zentek’s issued capital, a critical disclosure ensuring the independence and objectivity of Atrium’s research. This transparency is essential to mitigate conflicts of interest inherent in sponsored research arrangements.
Company-sponsored research, also known as issuer-paid research, is recognized within Canadian equity markets, particularly for smaller-cap companies listed on the TSXV or Canadian Securities Exchange that may lack coverage from traditional sell-side brokers. Regulatory bodies require full disclosure of such commercial relationships, which Zentek’s announcement fulfills by detailing compensation, term length, and the arm’s-length nature of the parties.
Zentek’s Dual Listing and Expanding Technology Portfolio
Zentek describes itself as a Canadian intellectual property development and commercialization company advancing graphene-enabled and advanced material technologies across clean air, next-generation materials, and critical minerals sectors. Its dual listing on the TSXV and NASDAQ reflects its strategy to access capital markets in both Canada and the U.S. The engagement of Atrium Research may be viewed as a strategic effort to boost visibility among diverse investor groups.
The announcement does not provide financial guidance, revenue forecasts, or updated operational timelines beyond previously disclosed information. The immediate market reaction to this news was not evident at the time of publication. Investors are advised to review all public regulatory filings, technical reports, and prior news releases alongside any sponsored research produced by Atrium under this agreement.
TSXV Approval Pending and Forward-Looking Statement Disclaimers
The Atrium research engagement remains subject to TSX Venture Exchange approval, without which the agreement is not fully effective. Zentek’s release includes standard forward-looking statements cautions, noting that future events and timelines involve risks and uncertainties, and there is no assurance that planned milestones will be achieved as scheduled or at all.
The company disclaims any obligation to update forward-looking information except as legally required. The TSX Venture Exchange and its Regulation Services Provider disclaim responsibility for the adequacy or accuracy of the release, a standard disclaimer for TSXV issuers. Investors should understand that forward-looking statements, including those related to PEA completion and commercial milestones, carry material risks and should not be relied upon as guarantees of future results.
